Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
WuXi Biologics (Cayman) Inc. - SIC # 8922 -
Ticker
Exchange
SIC #
Website
Latest Ticker
WXXWY
Over the counter
8922
www.wuxibiologics.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for WuXi Biologics (Cayman) Inc.
Is WuXi Biologics (SEHK:2269) Still Attractively Priced After Its 121% One Year Rebound
- Jan 16th, 2026 12:09 pm
JPM26: Bi- and multispecific modalities power Wuxi Biologics growth
- Jan 15th, 2026 4:32 am
JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth
- Jan 14th, 2026 9:00 pm
WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic
- Jan 12th, 2026 8:06 pm
WuXi Biologics Launches Industry-Leading Digital Twin Platform PatroLab™ Designed to Transform Bioprocessing and Manufacturing
- Jan 12th, 2026 6:09 am
Assessing WuXi Biologics (SEHK:2269) Valuation After New Sustainable Procurement Certification
- Jan 7th, 2026 4:14 pm
WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement
- Jan 4th, 2026 8:57 pm
WuXi Biologics Recognized by Hong Kong ESG Reporting Awards 2025 for Outstanding ESG Disclosure
- Dec 23rd, 2025 9:30 pm
WuXi Biologics Achieves CDP Highest "A" Ratings in Both Climate Change and Water Security
- Dec 19th, 2025 2:30 am
WuXi Biologics Extends Global CRDMO Network to Qatar Through Strategic MoU Signed with Qatar Free Zones Authority
- Dec 2nd, 2025 1:46 am
WuXi Biologics (SEHK:2269): Exploring Valuation After Recent Turnaround in Share Price Momentum
- Nov 11th, 2025 3:13 pm
Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London
- Nov 11th, 2025 6:00 am
WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index
- Oct 21st, 2025 6:30 pm
WuXi Biologics Honored with 2025 Global Customer Value Leadership Recognition by Frost & Sullivan
- Oct 20th, 2025 3:30 am
WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year
- Oct 9th, 2025 6:30 pm
WuXi Biologics (SEHK:2269) Valuation in Focus Following Recent Share Price Gains
- Oct 4th, 2025 7:47 am
The 2025 BPD Singapore Conference Has Concluded Successfully! Jointly Embarking on a New Journey for Global Development
- Sep 26th, 2025 7:00 pm
WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™,to Accelerate Biologics Development with High Titer and Superior Stability
- Sep 25th, 2025 5:42 am
WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year
- Sep 22nd, 2025 10:00 pm
Three WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tıbbi Cihaz Kurumu (TITCK)
- Sep 16th, 2025 10:00 pm
Scroll